Loading
Monoclonal and Polyclonal Antibodies Research / Platelet Disorders and Treatments · Journal article
Science Immunology · August 14, 2026
Encouraging direction, but not yet definitive.
This is a mechanistic and preclinical study demonstrating that fusion of IgG antibodies to albumin reduces transplacental transport via FcRn while preserving plasma half-life. The effect is shown in mouse models and ex vivo human placental tissue, and functional benefit is demonstrated in a fetal alloimmune thrombocytopenia model, but clinical efficacy and safety remain unproven.
Preclinical mechanistic study: mouse models, ex vivo human placental perfusion system, and mouse disease model. Mouse models (strain not specified); ex vivo human placental tissue (source, number of donors, and gestational age not specified); disease model used mice with induced fetal and neonatal alloimmune thrombocytopenia. Intervention: Fusion of IgG or Fab fragments to albumin (engineered for enhanced FcRn binding in some experiments). Compared with: Native IgG; albumin alone in transport assays.
Albumin fusion markedly reduced transplacental IgG transport in both mouse models and ex vivo human placental tissue FcRn-mediated prolonged plasma half-life was preserved after albumin fusion Fragment antigen–binding (Fab) fragments fused to engineered albumin showed minimal fetal exposure
No safety or tolerability data for albumin fusion constructs in living animals
This work presents a potential strategy to allow safe use of IgG-based therapeutics during pregnancy by reducing fetal exposure while maintaining maternal efficacy. Clinical translation would require demonstration of safety and efficacy in human pregnancy.
Sound preclinical and ex vivo mechanistic work demonstrating a proof-of-concept approach to reduce placental IgG transport, with a functional disease model showing attenuation of fetal pathology, but requiring clinical translation.
As stated by the source record.
This work presents a potential strategy to allow safe use of IgG-based therapeutics during pregnancy by reducing fetal exposure while maintaining maternal efficacy. Clinical translation would require demonstration of safety and efficacy in human pregnancy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immunoglobulin G (IgG)–based monoclonal antibodies are effective therapies for cancer, autoimmune diseases, and migraine. However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy. Using mouse models and an ex vivo human placental perfusion system, we show that although FcRn binds albumin independently of IgG, albumin is not transported to the fetus in mice or across human placental tissue. Fusion of IgG to albumin markedly reduced transplacental transport in both models while preserving the prolonged plasma half-life conferred by FcRn. Similarly, fragment antigen–binding fragments fused to engineered albumin with enhanced FcRn binding showed minimal fetal exposure. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, albumin fusion of an anti–human platelet antigen IgG reduced fetal antibody transfer and attenuated thrombocytopenia in the offspring. These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.